公开(公告)号：US20140315932A1

公开(公告)日：2014-10-23

申请号：US14322165

申请日：2014-07-02

Applicant: NOVARTIS AG

Inventor： Timothy John RITCHIE ,  Andrew James CULSHAW ,  Christopher Thomas BRAIN ,  Edward Karol DZIADULEWICZ ,  Terance William HART

IPC: C07D401/04 ,  C07D239/91

CPC classification number: C07D401/04 ,  C07D239/91

Abstract: The present specification relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form.

Abstract translation: 本说明书涉及式（I）的喹唑啉酮化合物的用途，其中R 1，R 2，R 3，R 4，R 5和m如说明书和权利要求中所定义，为游离形式或盐形式， 在可能的情况下，以酸加成盐形式。

公开(公告)号：US20240043428A1

公开(公告)日：2024-02-08

申请号：US18069646

申请日：2022-12-21

Applicant: Novartis AG ,  Astex Therapeutics Ltd.

Inventor： Gilbert BESONG ,  Christopher Thomas BRAIN ,  Clinton A. BROOKS ,  Miles Stuart CONGREVE ,  Claudio DAGOSTIN ,  Guo HE ,  Ying HOU ,  Steven HOWARD ,  Yue LI ,  Yipin LU ,  Paul MORTENSON ,  Troy SMITH ,  Moo Je SUNG ,  Steven WOODHEAD ,  Wojciech WRONA ,  Bharat LAGU

IPC: C07D487/04 ,  A61K31/519 ,  C07D487/08 ,  A61P35/00

CPC classification number: C07D487/04 ,  A61P35/00 ,  C07D487/08 ,  A61K31/519

Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

公开(公告)号：US20210253578A1

公开(公告)日：2021-08-19

申请号：US17023041

申请日：2020-09-16

Applicant: Novartis AG ,  Astex Therapeutics Ltd.

Inventor： Gilbert BESONG ,  Christopher Thomas BRAIN ,  Clinton A. BROOKS ,  Miles Stuart CONGREVE ,  Claudio DAGOSTIN ,  Guo HE ,  Ying HOU ,  Steven HOWARD ,  Yue LI ,  Yipin LU ,  Paul MORTENSON ,  Troy SMITH ,  Moo Je SUNG ,  Steven WOODHEAD ,  Wojciech WRONA ,  Bharat LAGU

IPC: C07D487/04 ,  C07D487/08 ,  A61K31/519 ,  A61P35/00

Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

公开(公告)号：US20130184285A1

公开(公告)日：2013-07-18

申请号：US13786955

申请日：2013-03-06

Applicant: NOVARTIS AG ,  ASTEX THERAPEUTICS

Inventor： Christopher Thomas BRAIN ,  Moo Je SUNG ,  Bharat LAGU

IPC: C07D487/04

CPC classification number: C07D487/04 ,  A61K31/519 ,  C07D487/08

Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

Abstract translation: 所公开的化合物涉及蛋白激酶相关病症的治疗和疗法。 还需要可用于治疗或预防或改善癌症，移植排斥和自身免疫性疾病的一种或多种症状的化合物。 此外，需要使用本文提供的化合物调节蛋白激酶如CDK1，CDK2，CDK4，CDK5，CDK6，CDK7，CDK8和CDK9的活性的方法。